Key Benefits
• Binds specifically to H. pylori surface proteins, forming coaggregates• Flushes H. pylori out of the GI tract – does not kill, but physically removes• Reduces gastric H. pylori load significantly and sustainably• Alleviates mild dyspepsia symptoms
Key Data
• Coaggregation occurs within seconds in vitro• Single DSM17648 cell binds 2–3 H. pylori cells• Active in 37°C artificial gastric juice; effective across pH 2–8 (covering fasting to post-meal gastric pH range)• Not interfered by common dietary sugars; requires pepsin for full activation• Clinical trial: 2‑week monotherapy eradication rate: 54% ; 8‑week monotherapy: approaches triple-drug antibiotic therapy at 65%• Excellent safety profile – side‑effect free (physical binding mechanism, not pharmacological)
Commercial Use
Included in oral health / H. pylori‑targeted probiotic blends (chewable tablets)
Why Choose DSM17648?
Mechanistically unique – physical binding and excretion, not killing or bacteriostatic action; mimics natural immune defense without disrupting gut microbiota balance
Clinically validated with multiple human trials; comparable efficacy to antibiotic therapy in 8‑week use, without side effects or resistance risk
Highly stable – active across a wide pH range (2–8); compatible with various formulations including tablets, powders, and beverages
Ideal for functional foods and supplements targeting H. pylori‑positive populations, chronic gastritis sufferers, and consumers seeking antibiotic‑free gut health solutions
Strong consumer appeal – “gentle removal” positioning avoids the stigma of antibiotic-associated side effects